GlassScriptPhysician profile
Johnathan C Baines
NPI 1679769889
$3,706.60
in general payments reported to CMS, 2019-2025
32 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $401 · 2021: $514 · 2022: $713 · 2023: $782 · 2024: $401 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763 · Education: $33.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.97 |
| Education | $33.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $619.26 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $599.07 | 2022-2025 | |
| Lilly USA, LLC | $433.15 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $375.18 | 2019-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.87 | 2019-2023 | |
| Corcept Therapeutics | $196.99 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $167.84 | 2019-2025 | Farxiga |
| Abbvie INC. | $146.78 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $114.73 | 2021-2023 | Seglentis, Livalo |
| Pfizer INC. | $100.08 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.63 | 2022-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.38 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $68.00 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Abbott Laboratories | $58.88 | 2021-2025 | Freestyle Libre 3 |
| Nevro Corp. | $54.52 | 2022-2023 | Senza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $54.42 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $50.33 | 2021-2025 | Shingrix |
| Sumitomo Pharma America, INC. | $29.68 | 2023-2025 | Gemtesa |
| Insulet Corporation | $26.20 | 2025 | Omnipod |
| Mylan Specialty L.P. | $23.99 | 2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $21.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.94 | 2021 | |
| Inogen, INC. | $19.80 | 2023 | Inogen At Home Stationary Concentrator |
| Abiomed | $19.47 | 2025 | |
| Dexcom, INC. | $18.51 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $18.38 | 2025 | |
| Paratek Pharmaceuticals, INC. | $16.63 | 2022 | |
| Evoke Pharma, INC. | $16.17 | 2024 | |
| Daiichi Sankyo INC. | $15.55 | 2022 | |
| Irhythm Technologies, INC. | $14.32 | 2019 | |
| Eisai INC. | $13.81 | 2021 | |
| Esperion Therapeutics, INC. | $12.73 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Baines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.